A5087844093- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Neutropenia and Cancer Infections
- Chronic Lymphocytic Leukemia Research
- Histone Deacetylase Inhibitors Research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Hematological disorders and diagnostics
- Cancer therapeutics and mechanisms
- T-cell and Retrovirus Studies
- Blood groups and transfusion
- Protein Degradation and Inhibitors
- Hemoglobinopathies and Related Disorders
- Cutaneous lymphoproliferative disorders research
- Cytomegalovirus and herpesvirus research
- Viral-associated cancers and disorders
- Renal Transplantation Outcomes and Treatments
- Complement system in diseases
- Platelet Disorders and Treatments
- Drug-Induced Hepatotoxicity and Protection
Ankara Onkoloji Eğitim ve Araştırma Hastanesi
2017-2025
Sağlık Bilimleri Üniversitesi
2017-2025
University of Health Science
2019-2023
Ankara Yıldırım Beyazıt University
2021-2023
University of Health Sciences
2019-2023
Ministry of Health
2021-2023
Weatherford College
2020-2022
Sakarya University
2021
University Hospital Ulm
2020
Kent and Canterbury Hospital
2020
Although induction chemotherapy results in remission many older patients with acute myeloid leukemia (AML), relapse is common and overall survival poor.
Granulocyte colony-stimulating factor (G-CSF) is the most prevalently used growth for peripheral blood hematopoietic stem cell (HSC) mobilization. Most centers split granulocyte in two daily doses, whereas some administer one dose per day. This study aims to investigate effect of filgrastim dosing schedule on quantity cells collected after mobilization healthy donors. A total 251 donors mobilized our center were included study. Mobilization was either once a day (filgrastim 1 × 10 mg/kg/day)...
Abstract The aim of this study was to identify indicators outcome prior transplantation in allogeneic hematopoietic stem cell ( HCT ). Clinical data 106 patients with acute leukemia were retrospectively analyzed. We examined the role pre‐conditioning serum C ‐reactive protein CRP ) and ferritin levels, ‐ CI E uropean G roup for B lood M arrow T ransplantation EBMT scores on transplant toxicities, transplant‐related mortality TRM ), progression‐free survival PFS overall OS High levels showed...
The prognosis is poor for relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) patients. brentuximab vedotin (Bv) and bendamustine (B) combination has been used as a preferable salvage regimen in R/R cHL patient trials. We retrospectively evaluated response rates, toxicities, the survival patients treated with BvB combination. In multi-centre real-life study, 61 HL received intravenous doses of 1.8 mg/kg Bv on first day plus 90 mg/m2 B second days 21-day cycle second-line...
A multicenter, retrospective, observational study was conducted to explore effectiveness and safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM) patients following at least ≥ two lines therapy. Patients' treatment responses, overall response rate, progression-free survival adverse events were recorded. Mean age 54 66.5 ± 9.1 years. There 20 (37.0%) progression. Median 13 months who received a median three therapy 7.5-month follow-up...
Gemcitabine, dexamethasone and cisplatin (GDP) is a well-established salvage regimen for relapsed refractory lymphomas. In this study, we aimed to share our experience with the patients who received GDP/R-GDP (rituximab-gemcitabine, cisplatin) stem cell mobilization.Data of 69 Hodgkin lymphoma (HL) Non-Hodgkin (NHL) as chemotherapy in center between July 2014 January 2020 were retrospectively evaluated. After evaluation response, 52 had chemosensitive disease underwent mobilization plus...
Objective: The aim of this study was to use flow cytometry analyze the expression cell cycle-regulating elements with low and high proliferative signatures in patients malignant diseases.Material Methods: Cyclin D, E, A, B, cyclin-dependent kinase inhibitor (CDKI) p16 p21 levels were measured via chronic myeloid leukemia (CML) (n = 16) multiple myeloma (MM) 13), controls 15).Results: distributions cycle S phase 10, 63%, 6, 72% 3, 59%; for CML, MM control patients, respectively.Among all...
: The Wilms' tumor gene 1 (WT1) plays a critical role in cell development and the regulation of essential genes involved growth metabolism. In context hematopoietic tumors, including acute myeloid leukemia (AML), WT1 has been identified as potential marker for measurable residual disease (MRD) assessment. Relapse after allogeneic stem transplantation (allo-SCT) remains significant challenge AML treatment, highlighting importance MRD monitoring risk stratification treatment decisions. This...
Abstract Rationale: Relapsed or refractory peripheral T-cell lymphomas are aggressive diseases. Pralatrexate is an antimetabolite. Hereby, we reporting a pralatrexate induced durable response in relapsed/refractory T-Cell lymphoma patient with history of autologous stem cell transplantation. Patient concerns: A male born February 1947 was diagnosed based on his cervical lymph node excisional biopsy. Diagnoses: He PTCL-NOS 19, 2013. Interventions: The received 6 cycles CHOP (Cyclophosphamide,...
ÖZETGİRİŞ ve AMAÇ: Akut lenfoblastik lösemi (ALL), hematopoietik lenfoid öncüllerinden kaynaklanan blastların anormal çoğalmasından kaynaklanır.ALL, pediatrik vakalarının % 75'ini oluşturur yetişkinlerde 1.28/100.000insidansı vardır.ALL etiyolojisi hala tartışma konusudur.Bazı çalışmalarda, ABO kan gruplarının kardiyovasküler, onkolojik diğer hastalıkların gelişiminde rol oynadığı gösterilmiştir.Bu çalışmada ALL ile Rh grupları arasındaki ilişkileri araştırmayı amaçladık.YÖNTEM GEREÇLER: Merkezimizde
Introduction: Multiple Myeloma (MM) is a common hematological malignancy and various factors affect survival.Uric acid (UA) an easily quickly accessible laboratory test.UA has been found to prognosis survival in many diseases its impact on myeloma not widely investigated.Methods: Our retrospective study includes 106 MM patients between 2014 2021.The influence of UA level at diagnosis treatment outcomes who received autologous stem cell transplantation (ASCT) was investigated. Results:The...
Introduction: Chronic myelomonocytic leukemia (CMML) is a condition that overlaps with myelodysplastic syndrome and myeloproliferative neoplasms.The prognosis generally poor, median survival of 20 to 40 months approximately 15-30% patients progressing acute myeloid (AML).We aimed evaluate the characteristics outcomes CMML who were treated at our institution. Material methods:A retrospective cohort study examined data from 14 between January 2013 2022.Results: The age fourteen diagnosis was...
We report a 42-year-old patient who had Hodgkin lymphoma and developed bilateral symmetrical peripheral gangrene (SPG) in the feet hands, which occurred during septic shock after autologous hematopoietic stem-cell transplantation. SPG is rare but severe complication of disseminated intravascular coagulation (DIC) frequently associated with sepsis. The pathophysiology includes DIC-mediated thrombosis thrombotic occlusion microcirculation, resulting low blood flow. Sepsis-induced hypotension...
We hereby report our multicentre, retrospective experience with CLARA in patients fludarabine/cytarabine/G-CSF (FLAG) refractory AML. The study included all consecutive R/R AML patients, who received salvage during October 2010–October 2015 period. All were unresponsive to FLAG chemotherapy regimen and did not undergo previous allo-HCT. A total of 40 included. Following 5 (12.5%) experienced induction mortality 10 (25%) achieved CR. 25 (62.5%) CLARA. 7 (17.5%) out CR Median overall survival...